RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BARBERO P
Collezione AOU San Luigi di Orbassano

Items : 8

Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology / Neurol Sci. 2020 Oct;41(10):2781-2792. doi: 10.1007/s10072-020-04392-8. Epub 2020 Apr 12.

2020
AOU San Luigi di Orbassano

Moccia M; Frau J; Carotenuto A; Butera C; Coghe G; Barbero P; Frontoni M; Groppo E; Giovannelli M; Del Carro U; Inglese C; Frasson E; Castagna A; Buccafusca M; Latino P; Nascimbene C; Romano M; Liotti V; Lanfranchi S; Rapisarda L; Lori S; Esposito M; Maggi L; Petracca M; Lo Fermo S; Altavista MC; Bono F; Eleopra R; Brescia Morra V; et alii...

Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study. in Parkinsonism & related disorders / Parkinsonism Relat Disord. 2019 May;62:231-235. doi: 10.1016/j.parkreldis.2018.11.003. Epub 2018 Nov

2019
AOU San Luigi di Orbassano

Artusi CA; Bortolani S; Merola A; Zibetti M; Busso M; De Mercanti S; Arnoffi P; Martinetto S; Gaidolfi E; Veltri A; Barbero P; Lopiano L;

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia. in Journal of neurology / J Neurol. 2015 Dec;262(12):2662-7. doi: 10.1007/s00415-015-7894-1. Epub 2015 Sep 26.

2015
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Durelli L; Chio' A; Calvo A; Avagnina P; Veltri A; Cucci A; De Mercanti S; Artusi CA; Tinivella M; Busso M; Barbero P; Clerico M;

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose. in Journal of neuroimmunology / J Neuroimmunol. 2010 Sep 14;226(1-2):150-7. doi: 10.1016/j.jneuroim.2010.05.038. Epub 2010 Jun 23.

2010
AOU San Luigi di Orbassano

Cucci A; Barbero P; Clerico M; Ferrero B; Versino E; Contessa G; Demercanti S; Viglietta E; Di Liberto A; Vai AG; Durelli L;

Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b. in Expert opinion on biological therapy / Expert Opin Biol Ther. 2009 Apr;9(4):387-97. doi: 10.1517/14712590902762781.

2009
AOU San Luigi di Orbassano

Durelli L; Barbero P; Cucci A; Ferrero B; Ricci A; Contessa G; De Mercanti S; Ripellino P; Lapuma D; Viglietta E; Bergui M; Versino E; Clerico M;

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders. in Journal of neurology / J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25.

2008
AOU San Luigi di Orbassano

Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. in Journal of neurology, neurosurgery, and psychiatry / J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):646-51. doi: 10.1136/jnnp.2007.130229. Epub 2007 Nov 6

2008
AOU San Luigi di Orbassano

Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Rivoiro C; Ferrero C; Picco E; Ripellino P; Giuliani G; Montanari E; Clerico M; Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Rivoiro C; Ferrero C; Picco E; Ripellino P; Giuliani G; Montanari E; Clerico M;

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. in Journal of the neurological sciences / J Neurol Sci. 2004 Jul 15;222(1-2):13-9. doi: 10.1016/j.jns.2004.03.023.

2004
AOU San Luigi di Orbassano

Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L;